A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients.

Trial Profile

A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Aliskiren (Primary) ; Telmisartan (Primary)
  • Indications Essential hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms ASSERTIVE
  • Sponsors Novartis
  • Most Recent Events

    • 21 Apr 2012 Results presented at the 18th World Congress of Cardiology.
    • 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
    • 20 Jun 2011 Substudy results presented at the 21st European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top